Department of Radiation Oncology, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
Clin Cancer Res. 2020 Jan 1;26(1):265-273. doi: 10.1158/1078-0432.CCR-19-0610. Epub 2019 Oct 1.
The identification of novel targets for developing synergistic drug-radiation combinations would pave the way to overcome tumor radioresistance. We conducted cell-based screening of a human kinome siRNA library to identify a radiation-specific kinase that has a synergistic toxic effect with radiation upon inhibition and is not essential for cell survival in the absence of radiation.
Unbiased RNAi screening was performed by transfecting A549 cells with a human kinome siRNA library followed by irradiation. Radiosensitizing effects of a target gene and involved mechanisms were examined.
We identified the nonreceptor protein tyrosine kinase (FEline Sarcoma oncogene) as a radiosensitizing target. The expression of FES was increased in response to irradiation. Cell viability and clonogenic survival after irradiation were significantly decreased by FES knockdown in lung and pancreatic cancer cell lines. In contrast, FES depletion alone did not significantly affect cell proliferation without irradiation. An inducible RNAi mouse xenograft model verified radiosensitizing effects. FES-depleted cells showed increased apoptosis, DNA damage, G-M phase arrest, and mitotic catastrophe after irradiation. FES depletion promoted radiation-induced reactive oxygen species formation, which resulted in phosphorylation of S6K and MDM2. The radiosensitizing effect of FES knockdown was partially reversed by inhibition of S6K activity. Consistent with the increase in phosphorylated MDM2, an increase in nuclear p53 levels was observed, which appears to contribute increased radiosensitivity of FES-depleted cells.
We uncovered that inhibition of FES could be a potential strategy for inducing radiosensitization in cancer. Our results provide the basis for developing novel radiosensitizers.
确定用于开发协同药物-辐射组合的新靶标将为克服肿瘤放射抵抗铺平道路。我们对人类激酶组 siRNA 文库进行了基于细胞的筛选,以鉴定一种具有辐射特异性的激酶,该激酶在抑制时与辐射具有协同毒性作用,并且在没有辐射的情况下对细胞存活不是必需的。
通过用人类激酶组 siRNA 文库转染 A549 细胞,然后进行辐射,进行无偏 RNAi 筛选。检查了靶基因的放射增敏作用及其涉及的机制。
我们将非受体蛋白酪氨酸激酶(FEline Sarcoma 癌基因)鉴定为放射增敏靶标。FES 的表达在照射后增加。在肺和胰腺癌细胞系中,FES 敲低显着降低了照射后的细胞活力和克隆存活。相比之下,单独的 FES 耗竭在没有照射的情况下对细胞增殖没有显着影响。可诱导的 RNAi 小鼠异种移植模型验证了放射增敏作用。照射后,FES 耗尽的细胞显示出增加的细胞凋亡、DNA 损伤、G-M 期停滞和有丝分裂灾难。FES 耗竭促进了辐射诱导的活性氧形成,导致 S6K 和 MDM2 的磷酸化。通过抑制 S6K 活性,部分逆转了 FES 敲低的放射增敏作用。与磷酸化 MDM2 的增加一致,观察到核 p53 水平增加,这似乎有助于增加 FES 耗尽细胞的放射敏感性。
我们发现抑制 FES 可能是诱导癌症放射增敏的潜在策略。我们的结果为开发新型放射增敏剂提供了基础。